Literature DB >> 26556905

Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer.

I Meinhold-Heerlein1, C Fotopoulou2, P Harter3, C Kurzeder3, A Mustea4, P Wimberger5, S Hauptmann6, J Sehouli2.   

Abstract

More than 25 years after the last revision, in 2012 the FIGO Oncology Committee began revising the FIGO classification for staging ovarian, Fallopian tube and primary peritoneal cancers. The new classification has become effective with its publication at the beginning of 2014. Following recent findings on the pathogenesis of ovarian, Fallopian tube and primary peritoneal cancer and reflecting standard clinical practice, the three entities have now been classified uniformly. The histological subtype is included (high-grade serous - HGSC; low-grade serous - LGSC; mucinous - MC; clear cell - CCC; endometrioid - EC). Stages III and IV have been fundamentally changed: stage IIIA now refers to a localized tumor limited to the pelvis with (only) retroperitoneal lymph node metastasis (formerly classified as IIIC). Stage IV has been divided into IVA and IVB, with IVA defined as malignant pleural effusion and IVB as parenchymatous or extra-abdominal metastasis including inguinal and mediastinal lymph node metastasis as well as umbilical metastasis. A new WHO classification was published almost concurrently. The classification of serous tumors addresses the issue of the tubal carcinogenesis of serous ovarian cancer, even if no tubal precursor lesions are found for up to 30 % of serous high-grade cancers. The number of subgroups was reduced and subgroups now include only high-grade serous, low-grade serous, mucinous, seromucinous, endometrioid, clear cell and Brenner tumors. The category "transitional cell carcinomas" has been dropped and the classification "seromucinous tumors" has been newly added. More attention has been focused on the role of borderline tumors as a stage in the progression from benign to invasive lesions.

Entities:  

Keywords:  FIGO stage; borderline tumor; ovarian cancer subtypes

Year:  2015        PMID: 26556905      PMCID: PMC4629993          DOI: 10.1055/s-0035-1558079

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  23 in total

1.  FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics.

Authors:  S Pecorelli; J L Benedet; W T Creasman; J H Shepherd
Journal:  Int J Gynaecol Obstet       Date:  1999-06       Impact factor: 3.561

2.  FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics.

Authors:  S Pecorelli; J L Benedet; W T Creasman; J H Shepherd
Journal:  Int J Gynaecol Obstet       Date:  1999-01       Impact factor: 3.561

3.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum.

Authors:  Jaime Prat
Journal:  Int J Gynaecol Obstet       Date:  2013-10-22       Impact factor: 3.561

Review 4.  Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update.

Authors:  Felix Zeppernick; Ivo Meinhold-Heerlein; Ie-Ming Shih
Journal:  J Obstet Gynaecol Res       Date:  2014-10-20       Impact factor: 1.730

Review 5.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

6.  The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.

Authors:  Gautier Chene; Veronique Ouellet; Kurosh Rahimi; Veronique Barres; Diane Provencher; Anne Marie Mes-Masson
Journal:  Int J Gynaecol Obstet       Date:  2015-04-11       Impact factor: 3.561

7.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

Review 8.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

9.  [New FIGO classification of ovarian, fallopian tube and primary peritoneal cancer].

Authors:  A K Höhn; J Einenkel; C Wittekind; L-C Horn
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

10.  Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture.

Authors:  Dong Hoon Suh; Tae Hun Kim; Jae-Weon Kim; Sun Young Kim; Hee Seung Kim; Taek Sang Lee; Hyun Hoon Chung; Yong-Beom Kim; Noh Hyun Park; Yong Sang Song
Journal:  J Gynecol Oncol       Date:  2013-10-02       Impact factor: 4.401

View more
  11 in total

1.  Mucinous borderline ovarian tumors: Analysis of 75 patients from a single center.

Authors:  Duygu Kavak Cömert; Işın Üreyen; Alper Karalok; Tolga Taşçı; Osman Türkmen; Reyhan Öcalan; Taner Turan; Gökhan Tulunay
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-01-12

Review 2.  The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications.

Authors:  L R Duska; E C Kohn
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

Review 3.  Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer.

Authors:  Natasha Rinne; Elizabeth L Christie; Anastasia Ardasheva; Chun Hei Kwok; Nikita Demchenko; Caroline Low; Catherine Tralau-Stewart; Christina Fotopoulou; Paula Cunnea
Journal:  Cancer Drug Resist       Date:  2021-04-14

4.  Impact of age on clinicopathological features and survival of epithelial ovarian neoplasms in reproductive age.

Authors:  Maya Hanatani; Nobuhisa Yoshikawa; Kosuke Yoshida; Satoshi Tamauchi; Yoshiki Ikeda; Kimihiro Nishino; Kaoru Niimi; Shiro Suzuki; Michiyasu Kawai; Hiroaki Kajiyama; Fumitaka Kikkawa
Journal:  Int J Clin Oncol       Date:  2019-09-20       Impact factor: 3.402

5.  Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.

Authors:  Angelo Di Giorgio; Pierandrea De Iaco; Michele De Simone; Alfredo Garofalo; Giovanni Scambia; Antonio Daniele Pinna; Giorgio Maria Verdecchia; Luca Ansaloni; Antonio Macrì; Paolo Cappellini; Valerio Ceriani; Giorgio Giorda; Daniele Biacchi; Marco Vaira; Mario Valle; Paolo Sammartino
Journal:  Ann Surg Oncol       Date:  2016-11-28       Impact factor: 5.344

6.  Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.

Authors:  Ann Rita Halvorsen; Gunnar Kristensen; Andy Embleton; Cybil Adusei; Maria Pilar Barretina-Ginesta; Philip Beale; Åslaug Helland
Journal:  Dis Markers       Date:  2017-02-15       Impact factor: 3.434

7.  Tetrandrine Reverses Paclitaxel Resistance in Human Ovarian Cancer via Inducing Apoptosis, Cell Cycle Arrest Through β-Catenin Pathway.

Authors:  Luo Jiang; Rui Hou
Journal:  Onco Targets Ther       Date:  2020-04-30       Impact factor: 4.147

8.  Performance of pre-treatment ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography for detecting metastasis in ovarian cancer: a systematic review and meta-analysis.

Authors:  Sangwon Han; Sungmin Woo; Chong Hyun Suh; Jong Jin Lee
Journal:  J Gynecol Oncol       Date:  2018-11       Impact factor: 4.401

9.  Ovarian seromucinous tumors: clinicopathological features of 10 cases with a detailed review of the literature.

Authors:  Romana Idrees; Nasir Ud Din; Sabeehudin Siddique; Saira Fatima; Jamshid Abdul-Ghafar; Zubair Ahmad
Journal:  J Ovarian Res       Date:  2021-03-18       Impact factor: 4.234

10.  The maximum standardized uptake value and extent of peritoneal involvement may predict the prognosis of patients with recurrent ovarian cancer after primary treatment: A retrospective clinical study.

Authors:  Yuanyuan Jiang; Guozhu Hou; Fengyu Wu; Zhaohui Zhu; Wei Zhang; Wuying Cheng
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.